Shares of Syncom Formulations (India) Limited vaulted 10.7% to INR 19.19 on August 28 as investors continued piling into the stock following a June-quarter earnings report that showed profits surging well beyond revenue growth — a combination that signals improving efficiency but also raises questions about durability at this price level. Syncom Formulations Rockets Past Its 52-Week High on a 58% Profit Jump — Can a Tiny Drugmaker Keep This Rally Alive?
Shares surged 10.7% to INR 19.19 on August 28, blowing past the stock's prior 52-week high, as buyers continued digesting a June-quarter earnings report that showed profit growth wildly outpacing revenue. Classified by SEBI as a small-cap company , Syncom Formulations is a generic-drug manufacturer that just posted the kind of numbers usually reserved for much larger peers — and the market is scrambling to price that in.
Profit Nearly Doubled While Sales Barely Budged — That's the Real Story
Profit before tax rose 59% to INR 32.25 crore, while profit after tax increased roughly 58% to INR 24.85 crore , compared with INR 15.75 crore a year earlier. Sales rose just 7.38% to INR 125.53 crore . The gap between those two numbers is enormous: net profit margin jumped to 18.63% , meaning the company kept nearly one-fifth of every rupee earned. The company is almost debt-free , so more of that profit flows directly to shareholders.
A Leadership Shakeup Is Happening Quietly Behind the Earnings Party Overlooked amid the rally: the company announced two senior leadership changes effective August 11 — founder Kedarmal Bankda resigned as Director and CFO Rahul Bankda also stepped down . Managing Director Vijay Bankda also resigned the same day, with the company calling it a planned succession . Three top executives — all from the founding family — exiting simultaneously deserves investor scrutiny, regardless of the "no disagreements" language in the filings.
The Stock Is Now Priced for Perfection At INR 19.19, the stock has gained roughly 46% from its July 29 price of INR 13.11. The P/E ratio recently stood at 17.66 , but today's price pushes that closer to 20x trailing earnings — territory that analysts flagged as "expensive" even at lower prices in May . Cash conversion has historically been poor, with only about -14% of operating earnings converting to cash flow , a red flag for any stock trading at a premium.
A Small Dividend Sweetens the Deal — Slightly
The board recommended a final dividend of INR 0.10 per share , with the record date set for September 23. That's a token yield at current prices, but it signals confidence. The real question: whether disciplined cost control — the company's own explanation for the margin expansion — can survive a quarter where revenue actually fell 11% sequentially . One blowout quarter doesn't make a trend.